EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product

Jonas Pielenhofer iD, Sophie Luise Meiser, Karsten Gogoll, Anna-Maria Ciciliani, Mark Denny, Michael Klak, Berenice M Lang, Petra Staubach, Stephan Grabbe iD, Hansjörg Schild, Markus P Radsak iD, Hilde Spahn-Langguth und 1 weitere

Pharmaceutics · 03.02.2023 · 15 (2) · 514

DOI: 10.3390/pharmaceutics15020514 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 03.02.2023. Verfasst von Jonas Pielenhofer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department for Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128 Mainz, Germany. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, RMU Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present article exemplifies the application of the concept of quality by design (QbD) for the systematic development of a nanoparticulate imiquimod (IMQ) emulsion gel formulation as an investigational medicinal product (IMP) for evaluation in an academic phase-I/II clinical trial for the treatment of actinic keratosis (AK) against the comparator Aldara (EudraCT: 2015-002203-28). The design of the QbD elements of a quality target product profile (QTPP) enables the identification of the critical quality attributes (CQAs) of the drug product as the content of IMQ, the particle-size distribution, the pH, the rheological properties, the permeation rate and the chemical, physical and microbiological stability. Critical material attributes (CMAs) and critical process parameters (CPPs) are identified by using a risk-based approach in an Ishikawa diagram and in a risk-estimation matrix. In this study, the identified CPPs of the wet media ball-milling process’s milling time and milling speed are evaluated in a central composite design of experiments (DoEs) approach, revealing criticality for both factors for the resulting mean particle size, while only the milling time is significantly affecting the polydispersity. To achieve a mean particle size in the range of 300–400 nm with a minimal PdI, the optimal process conditions are found to be 650 rpm for 135 min. Validating the model reveals a good correlation between the predicted and observed values. Adequate control strategies were implemented for intermediate products as in-process controls (IPCs) and quality control (QC) tests of the identified CQAs. The IPC and QC data from 13 “IMI-Gel” batches manufactured in adherence to good manufacturing practice (GMP) reveal consistent quality with minimal batch-to-batch variability.

Schlagwörter

Stichwörter der Autor:innen

GMPIMI-Gelcritical quality attributesdesign of experimentsnanoparticlesquality target product profile

Autor:innen und Institutionen

  • Department for Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128 Mainz, Germany.
  • Department of Dermatology, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
  • Institute for Immunology, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
  • 3rd Department Internal Medicine, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany.

ORCID-Profile: Jonas Pielenhofer, Stephan Grabbe, Markus P Radsak

Förderung

  • Deutsche Forschungsgemeinschaft
  • RMU Initiative

Zitieren

APA

Pielenhofer, J., Meiser, S. L., Gogoll, K., Ciciliani, A. M., Denny, M., Klak, M., Lang, B. M., Staubach, P., Grabbe, S., Schild, H., Radsak, M. P., Spahn-Langguth, H., & Langguth, P. (2023). Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product. Pharmaceutics, 15(2), 514. https://doi.org/10.3390/pharmaceutics15020514

Vancouver

Pielenhofer J, Meiser SL, Gogoll K, Ciciliani AM, Denny M, Klak M, et al. Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product. Pharmaceutics. 2023;15(2):514. doi:10.3390/pharmaceutics15020514

BibTeX
@article{Pielenhofer2023,
  author = {Pielenhofer, Jonas and Meiser, Sophie Luise and Gogoll, Karsten and Ciciliani, Anna-Maria and Denny, Mark and Klak, Michael and Lang, Berenice M and Staubach, Petra and Grabbe, Stephan and Schild, Hansjörg and Radsak, Markus P and Spahn-Langguth, Hilde and Langguth, Peter},
  title = {Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {2},
  pages = {514},
  doi = {10.3390/pharmaceutics15020514}
}
Kostenlos starten →